The use of regular, low-dose, oral sustained-release morphine for 4 weeks in patients with COPD and moderate to very severe breathlessness has been shown to improve disease-specific health status.
Treatment with dupilumab led to significant improvements in lung function by 16 weeks and up to 24 weeks in patients with chronic rhinosinusitis with nasal polyps and comorbid asthma plus clinical features of COPD.
Patients with COPD who received a metered dose inhaler containing budesonide, glycopyrrolate, and formoterol fumarate showed lung function improvements through 52 weeks.
Nebulized ensifentrine, when added to tiotropium, produced clinically meaningful and significant improvements in lung function and quality of life in patients with COPD.
The FDA has approved Breztri Aerosphere (budesonide/glycopyrrolate/formoterol fumarate; AstraZeneca) for the maintenance treatment of chronic obstructive pulmonary disease.
Median prevalence of any underlying medical condition 47.2% for residents in all 50 states, DC.
ProAir® Digihaler® (albuterol sulfate; Teva) Inhalation Powder is now available for patients aged ≥4 years for the treatment or prevention of bronchospasm with reversible obstructive airway disease, and for the prevention of exercise-induced bronchospasm (EIB).
Eighteen RCTs with a total of 6086 patients were included in the analysis.
The Food and Drug Administration (FDA) has cleared the Propeller Health digital platform to connect with the Symbicort® Inhaler (budesonide, formoterol fumarate dihydrate; AstraZeneca), a corticosteroid and long-acting beta-2 agonist indicated for the treatment of asthma and COPD. The Propeller platform includes a sensor that is attached to the inhaler. The sensor delivers insights on…
Preemptive, patient-specific electronic messages from pulmonologists to primary care physicians improved guideline concordant care in COPD.
